Zeta Surgical
Zeta Surgical develops an AI-powered neuronavigation system that provides real-time, frameless surgical guidance with submillimeter accuracy without requiring head fixation or general anesthesia. The ZETA platform tracks patient movement 20 times per second, enabling image-guided interventions in operating rooms, emergency settings, and ambulatory centers. The system has received FDA 510(k) clearance for cranial…
Funding snapshot
About
Zeta Surgical develops an AI-powered neuronavigation system that provides real-time, frameless surgical guidance with submillimeter accuracy without requiring head fixation or general anesthesia. The ZETA platform tracks patient movement 20 times per second, enabling image-guided interventions in operating rooms, emergency settings, and ambulatory centers. The system has received FDA 510(k) clearance for cranial navigation, brain biopsy, ventriculostomy, and transcranial magnetic stimulation (TMS). Clinical studies demonstrate 100% single-pass catheter placement for external ventricular drains (vs 81% freehand), 0% revision surgeries (vs 19% freehand), and 0% adverse events (vs 28% freehand). The Zeta TMS Robotic System has also received FDA 510(k) clearance, achieving less than 1mm positional and less than 1 degree angular accuracy for repeated targeting across TMS therapy sessions. The system has been commercially deployed at HOPE Therapeutics clinics. Founded and headquartered in Boston, United States, the company has raised approximately $8.2 million at the seed stage.
Business model
Professional Service Robots > Healthcare > Surgery,
Healthcare IT > Provider > Administrative Solutions > HR > Learning & Development > Learning platforms > Simulation based > AR & VR > Surgery,
Neurology > Medical Devices > Therapeutic Devices > Neurosurgical Guidance System,
Surgical Instruments > Robotic Surgery
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.